Reagent: Raji Cells

Catalog Number: ARP-9944

Lot Number: 180191

Release Category: C

Provided: Each vial of ARP-9944 contains approximately \(4.3 \times 10^6\) cells in 1.0 mL of 70% RPMI containing 20% fetal bovine serum and 10% DMSO. Post-thaw viability was observed to be 29% but cells recovered quickly and reached 91% viability by day 4 of culture.

Cell Type: ARP-9944 is a human B cell line.

Propagation Medium: The recommended propagation medium is 90% RPMI containing 10% fetal bovine serum and supplemented with penicillin and streptomycin.

Freeze Medium: The recommended freeze medium is 70% RPMI containing 20% fetal bovine serum and 10% DMSO.

Growth Characteristics: ARP-9944 is a suspension cell line with a doubling time of approximately 20 hours.

Morphology: Lymphocytic

Sterility: Tests for bacteria, fungi and mycoplasma were negative.

Description: ARP-9944 is an Epstein Barr Virus (EBV)-positive Burkitt lymphoma line originally obtained from the American Type Culture Collection (ATCC).

Special Characteristics: ARP-9944 was used as the parental line in deriving Raji/DC-SIGN+ cells (ARP-9945). It is used as a negative control in DC-SIGN-mediated HIV transmission assays.

Recommended Storage: Keep at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer.

Contributor: Drs. Li Wu and Vineet N. KewalRamani


Citation: Acknowledgment for publications should read “The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Raji Cells, ARP-9944, contributed by Drs. Li Wu and Vineet N. KewalRamani.”

Biosafety Level: 2


Disclaimers: You are authorized to use this product for research use only. It is not intended for use in humans. Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.
While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Note:

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Jeffrey W. Thomas, NCI Technology Transfer Center, ATRF Room E3202, PO Box B, Frederick, MD 21701 at the following email address: jeffreyt@mail.nih.gov, before the reagent can be released. Please specify in the email the name and a description of the intended use of the reagent.

ATCC® is a trademark of the American Type Culture Collection.